MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday

Key Points

• Q1 2026 results due May 8: MAIA Biotechnology is set to report quarterly earnings before the market opens on Friday, May 8, with analysts projecting ($0.18) EPS.
• Recent performance and valuation: The stock opened at $1.33, trades between a 52-week low of $0.87 and high of $3.19, and has a market capitalization of about $80.7 million with 50- and 200-day moving averages near $1.51.
• Institutional activity is limited but growing: Small new stakes were reported from firms like Marshall Wace and Jane Street, Geode slightly increased its position, and institutional ownership remains low at 5.65%.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05.

MAIA Biotechnology Stock Performance

NYSEAMERICAN MAIA opened at $1.33 on Friday. MAIA Biotechnology has a 52 week low of $0.87 and a 52 week high of $3.19. The stock has a market capitalization of $80.69 million, a P/E ratio of -1.93 and a beta of 0.30. The stock has a fifty day moving average of $1.51 and a 200-day moving average of $1.52.

Institutional Trading of MAIA Biotechnology

Large investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology in the second quarter worth about $29,000. Jane Street Group LLC acquired a new position in MAIA Biotechnology in the 2nd quarter worth $52,000. Finally, Geode Capital Management LLC raised its stake in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after purchasing an additional 7,746 shares during the period. Institutional investors own 5.65% of the company's stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.